Transforming the future use of injectable medicines outside the hospital: Increasing capacity in the NHS

改变未来医院外注射药物的使用：提高 NHS 的能力

• 批准号: EP/X025470/1
• 负责人: Andrew Watts
• 金额: $ 427.92万
• 依托单位: University of Bath
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FX025470%2F1
• 关键词: Transforming; future; use; injectable; medicines

Aseptic compounding is an area where practice has been transformed by the emergence of more complex, personalised medicines. The demands on aseptic dispensing are continually increasing, with clinical teams relying on increasingly complex compounds for treatments given every single day.This Prosperity Partnership aims to create a platform that will transform the future use of injectable medicines in the UK and globally. We envisage, ultimately, a range of reformulated injectable medicines suited to the setting in which they are administered, whether in the community or a hospital, manufactured through an automated process dramatically reducing the demand placed on healthcare resource required to deliver them in whatever setting is appropriate. This potentially requires a wholesale reconfiguration of compounding service in England around a hub and spoke model with high degrees of standardisation and the adaption/adoption of new approaches to automation making more efficient use of resources both in pharmacy/compounding and in the nursing workforce transforming the use of injectable medicines. Underpinning the interlinked delivery of these medicines is a continual drive for extended shelf-lives (stability), simplicity in administration, volume of manufacture, supply chain and cost reduction.Our project focusses on the nexus of these points, considering medicine formulation, manufacture and distribution as a whole system, where elements of the compounding process can occur across different sites, with different scalability and optimisation depending on both use/requirement and shelf-life/complexity of formulation and aseptic manufacturing facility requirements. This incorporates implementing robotics manufacturing and AI into the heavily regulated area of high variation medicines production.

无菌复合是一个实践已被更复杂，个性化药物的出现所改变的领域。无菌配药的需求不断增加，临床团队每天都依赖越来越复杂的化合物进行治疗。这一繁荣合作伙伴关系旨在创建一个平台，将改变英国和全球注射药物的未来使用。我们设想，最终，一系列重新配制的注射药物适合于它们在其中被管理的环境，无论是在社区还是医院，通过自动化过程生产，大大减少了对在任何适当环境中提供它们所需的医疗资源的需求。这可能需要围绕具有高度标准化的中心辐射模型对英格兰的复合服务进行大规模重新配置，并适应/采用新的自动化方法，以便更有效地利用药房/复合和护理人员的资源，从而改变注射药物的使用。支持这些药物相互关联的交付是持续推动延长保质期（稳定性），管理简单，生产量，供应链和成本降低。我们的项目侧重于这些点的联系，将药物配方，生产和分销视为一个整体系统，其中配料过程的元素可以在不同的地点发生，根据制剂的使用/要求和保存期限/复杂性以及无菌生产设备要求，具有不同的可扩展性和优化性。这将机器人制造和人工智能应用到高度多样化的药品生产的严格监管领域。